文献速递儿童内分泌与遗传代谢儿童神经与发育行为儿童消化与营养

尿素循环障碍患儿临床特征及苯丁酸甘油酯疗效分析

[Clinical characteristics and efficacy of glyceryl phenylbutyrate treatment in 20 pediatric patients with urea cycle disorder].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2025-01-01

该回顾性单臂多中心研究纳入20例接受苯丁酸甘油酯(GPB)治疗的尿素循环障碍(UCD)患儿,分析其临床表现、实验室及分子遗传学特点,并评估GPB降氨疗效与安全性。结果显示GPB可降低血氨、血小板计数和天冬氨酸转氨酶水平,升高血清白蛋白,不良反应较轻且可自行缓解。

要点

  • UCD主要表现为神经和消化系统症状,血氨检测有助于早期诊断。
  • GPB治疗可降低患儿血氨水平,安全性和耐受性较好。
  • 鸟氨酸氨甲酰基转移酶缺乏症为最常见亚型,共检出27个变异中11个为新变异。

核心结论

  • UCD主要表现为神经和消化系统症状,可通过血氨检测早期明确诊断。
  • GPB可有效降低UCD患儿血氨水平,安全性耐受性较好。

研究设计与样本

  • 回顾性、单臂、多中心临床研究,收集9家医院2021年12月至2024年8月接受GPB治疗的20例UCD患儿临床资料。
  • 采用配对t检验或Wilcoxon检验评估GPB治疗前后血氨和其他实验室检查结果。

主要发现

  • 20例患儿中男8例、女12例,发病年龄2.8(1.4,5.7)岁,首次发病时血氨水平为174(125,342)μmol/L。
  • 临床表现包括呕吐6例、嗜睡5例、癫痫5例、发育落后5例、精神行为异常3例和精神萎靡1例,伴肝功能异常18例。
  • 病因涉及6种亚型,其中11例为鸟氨酸氨甲酰基转移酶缺乏症,共检出27个不同变异,其中11个(41%)为新变异。
  • GPB治疗年龄4.0(1.5,6.6)岁,治疗时长6.0(4.2,12.3)个月,末次随访时血氨、血小板计数和天冬氨酸转氨酶水平均低于治疗前(均P<0.05),血清白蛋白高于治疗前(P=0.016)。
  • 9例患儿发生可能与使用GPB相关的不良反应(食欲下降6例,呕吐3例,皮肤油脂味2例,嗜睡、乏力和腹泻各1例),相关症状于6(3,10)d后自行消失。

关键数值与推荐

  • 10例患儿GPB治疗4.2(3.4,5.3)个月后停用,其中4例肝移植、6例因经济原因。
  • 余10例GPB持续治疗11.6(8.6,14.0)个月。
  • 2例患儿各有1次急性高血氨发作,血氨水平分别为232和141 μmol/L。

临床怎么用

  • 对疑似UCD患儿应尽早检测血氨以明确诊断。
  • GPB可用于降低UCD患儿血氨水平,治疗期间需监测血氨、血小板计数、天冬氨酸转氨酶和血清白蛋白等指标。
  • 关注GPB相关不良反应如食欲下降、呕吐、皮肤油脂味等,多数症状可自行缓解。

局限性

  • 本研究为回顾性、单臂、多中心研究,样本量较小(20例)。
  • 部分患儿因肝移植或经济原因停用GPB,可能影响疗效评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical characteristics of urea cycle disorder (UCD), the efficacy and safety of glyceryl phenylbutyrate (GPB) therapy in pediatric patients with UCD. Methods: This study was a retrospective, single-arm, multicenter clinical study. The clinical data of 20 pediatric patients with UCD who received GPB treatment at 9 hospitals nationwide between December 2021 and August 2024 were collected. The clinical manifestations, laboratory results, and molecular genetic characteristics were analyzed, ammonia levels and other laboratory results were evaluated pre-post GPB therapy by paired t-tests or Wilcoxon tests. Results: Among the 20 pediatric patients with UCD, there were 8 males and 12 females, and the onset age was 2.8 (1.4, 5.7) years. The ammonia levels were 174 (125, 342) μmol/L at first onset. The symptoms included vomiting in 6 cases, drowsiness in 5 cases, epilepsy in 5 cases, developmental delay in 5 cases, psychiatric and behavioral abnormalities in 3 cases, and lethargy in 1 case, and 18 cases exhibited abnormal liver function. Twenty cases included 6 UCD subtypes, with 11 cases being ornithine transcarbamylase deficiency. A total of 27 variants were identified, 11 (41%) of which were novel. The age of patients who began GPB therapy was 4.0 (1.5, 6.6) years. Ten cases stopped GPB after 4.2 (3.4, 5.3) months, with 4 patients undergoing liver transplantation and 6 discontinuing for financial reasons. The remaining ten patients continued GPB therapy for 11.6 (8.6, 14.0) months. The duration of GPB treatment was 6.0 (4.2, 12.3) months, at the final visit, the levels of ammonia, platelets and aspartate aminotransferase were lower compared to those of pre-treatment (all P<0.05). The serum albumin level was higher than that of pre-treatment (P=0.016). Two patients suffered only one episode of acute hyperammonaemia, with ammonia levels of 232 and 141 μmol/L, respectively. Nine cases experienced adverse effects potentially related to GPB, decreased appetite in 6 cases, vomiting in 3 cases, abnormal skin oil odor in 2 cases, somnolence, fatigue and diarrhea each in 1 case, with symptoms improved within 6 (3, 10) days. Conclusions: UCD primarily manifests with neurological and gastrointestinal symptoms, and early diagnosis of UCD could be achieved through the analysis of ammonia. GPB may effectively reduce ammonia levels in UCD pediatric patients, with favorable safety and tolerability. 目的: 探讨尿素循环障碍(UCD)患儿临床特点及苯丁酸甘油酯(GPB)降氨疗效和安全性。 方法: 回顾性、单臂、多中心临床研究。收集9家医院2021年12月至2024年8月接受GPB治疗的20例UCD患儿的临床资料,分析其临床表现、实验室检查和分子遗传学特点,采用配对t检验或Wilcoxon检验评估GPB治疗前后血氨和其他实验室检查结果。 结果: 20例UCD患儿中男8例、女12例,发病年龄2.8(1.4,5.7)岁。首次发病时血氨水平为174(125,342)μmol/L,表现为呕吐6例、嗜睡5例、癫痫5例、发育落后5例、精神行为异常3例和精神萎靡1例,伴肝功能异常18例。20例患儿病因涉及6种亚型,其中11例为鸟氨酸氨甲酰基转移酶缺乏症。共检出27个不同变异,其中11个(41%)为新变异。20例患儿GPB治疗年龄4.0(1.5,6.6)岁,其中10例(4例肝移植,6例因经济原因)患儿GPB治疗4.2(3.4,5.3)个月后停用,余10例GPB持续治疗11.6(8.6,14.0)个月。GPB治疗时长6.0(4.2,12.3)个月,末次随访时血氨、血小板计数和天冬氨酸转氨酶水平均低于治疗前(均P<0.05),血清白蛋白高于治疗前(P=0.016)。2例患儿各有1次急性高血氨发作(232和141 μmol/L)。9例患儿发生可能与使用GPB相关的不良反应(食欲下降6例,呕吐3例,皮肤油脂味2例,嗜睡、乏力和腹泻各1例),相关症状于6(3,10)d后自行消失。 结论: UCD主要表现为神经和消化系统症状,可通过血氨检测早期明确诊断。GPB可有效降低UCD患儿血氨水平,安全性耐受性较好。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qiu WJ, Sun CK, Xiao Y, et al. [Clinical characteristics and efficacy of glyceryl phenylbutyrate treatment in 20 pediatric patients with urea cycle disorder]. Zhonghua Er Ke Za Zhi. 2025. PMID: 40835254. doi:10.3760/cma.j.cn112140-20250310-00193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。